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Reduced subcortical glutamate/glutamine in adults
with autism spectrum disorders: a [1H]MRS study
J Horder1,4, T Lavender1,4, MA Mendez1, R O’Gorman2, E Daly1, MC Craig1, DJ Lythgoe3, GJ Barker3 and DG Murphy1
Dysfunctional glutamatergic neurotransmission has been implicated in autism spectrum disorder (ASD). However, relatively few
studies have directly measured brain glutamate in ASD adults, or related variation in glutamate to clinical phenotype. We
therefore set out to investigate brain glutamate levels in adults with an ASD, comparing these to healthy controls and also
comparing results between individuals at different points on the spectrum of symptom severity. We recruited 28 adults with ASD
and 14 matched healthy controls. Of those with ASD, 15 fulfilled the ‘narrowly’ defined criteria for typical autism, whereas 13 met
the ‘broader phenotype’. We measured the concentration of the combined glutamate and glutamine signal (Glx), and other
important metabolites, using proton magnetic resonance spectroscopy in two brain regions implicated in ASD—the basal
ganglia (including the head of caudate and the anterior putamen) and the dorsolateral prefrontal cortex—as well as in a parietal
cortex ‘control’ region. Individuals with ASD had a significant decrease (Po0.001) in concentration of Glx in the basal ganglia, and
this was true in both the ‘narrow’ and ‘broader’ phenotype. Also, within the ASD sample, reduced basal ganglia Glx was significantly
correlated with increased impairment in social communication (P¼ 0.013). In addition, there was a significant reduction in the
concentration of other metabolites such as choline, creatine (Cr) and N-acetylaspartate (NAA) in the basal ganglia. In the
dorsolateral prefrontal cortex, Cr and NAA were reduced (Po0.05), although Glx was not. There were no detectable differences
in Glx, or any other metabolite, in the parietal lobe control region. There were no significant between-group differences in age,
gender, IQ, voxel composition or data quality. In conclusion, individuals across the spectrum of ASD have regionally specific
abnormalities in subcortical glutamatergic neurotransmission that are associated with variation in social development.
Translational Psychiatry (2013) 3, e279; doi:10.1038/tp.2013.53; published online 9 July 2013
Introduction
Autism spectrum disorder (ASD) is characterized by deficits in
social reciprocity, communication impairments, and
restricted, repetitive interests and behaviours.1 Recent
research suggests an approximate prevalence of 0.6–1.5%
in the general population.2
At present, however, therapeutic options for ASD are
limited because the pathophysiology of ASD is unclear,
leading to a paucity of treatment targets for the core
symptoms. Numerous studies have reported abnormalities
in brain anatomy and function of ASD individuals (e.g. see
Hallahan et al.3 and Barttfeld et al.4), but the underlying
molecular basis of these differences is unknown.
There is, however, emerging evidence suggesting that ASD
may be associated with abnormalities in excitatory glutamate
and inhibitory g-amino-butyric acid (GABA) neurotransmission.5
The balanced interaction between glutamate and GABA
transmission is essential for regulating cognition, learning,
memory and emotional behaviours. An imbalance between
glutamate excitation and GABA inhibition, leading to hyper-
excitation, has been linked to ASD.6–8
There is also evidence for an association between ASD
and genetic variation in the glutamatergic and GABAergic
systems. For example, there are reports of associations
between ASD and variants in genes coding for glutamate
receptors9,10 and glutamate transporter proteins,11 although
not in all studies.12 Also, recent work on fragile X syndrome,
the most common monogenetic syndrome associated with
ASD, points to the potential importance of metabotropic
glutamate receptors (mGluR1) as possible treatment targets
in ASD.13
Unfortunately, it is not possible to quantify glutamate and
GABA concentrations in post-mortem studies, because they
degrade rapidly after death. Progress can be made, however,
as in vivo proton magnetic resonance spectroscopy
([1H]MRS) can be used to quantify a range of neural
metabolites, including glutamate and its metabolic product
glutamine (GluþGln—henceforth abbreviated Glx).
There are six published [1H]MRS studies reported on Glx in
ASD. Of these, four investigated children, one reported a
widespread decrease in cortical Glx14 and another reported a
nonsignificant reduction in Glx in the left thalamic region.15
However, two other studies found no differences in any region
studied: one investigated the frontal, temporal and parietal
cortex and basal ganglia,16 and the other the frontal cortex
and basal ganglia.17
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Only two published [1H]MRS studies have measured Glx in
adults with ASD. Page et al.18 reported that adults with ASD
had a significantly higher concentration of Glx than controls in
the right amygdala-hippocampal complex. In contrast,
Bernardi et al.19 found a significantly lower Glx in the right
anterior cingulate cortex.
These prior investigations suggest that ASD individuals
may have differences in brain Glx, but the results are
inconsistent. Possible explanations for this mixed picture are
that some of these studies investigated relatively small
samples, and they examined different age groups and/or
brain regions. Also, no study of adults has yet addressed
whether any of these putative differences are present across
the behavioural spectrum (i.e. in both the ‘core’ disorder, and
those with the ‘broader phenotype’).
This is potentially of importance because while, in the past,
autism was generally treated as a ‘categorical’ diagnosis, it is
now understood to likely cover a spectrum of severity. For
example, the biological relatives of people with ASD often
show an attenuated ‘broader phenotype’ of mild social,
cognitive and neurobiological abnormalities.20
This clinical (and likely aetiological) heterogeneity has led
some to suggest that we refer to ‘the autisms’ rather than to
‘autism’ and search for final common pathways through which
various causative agents may lead to disorder.21 However,
previous [1H]MRS studies of adults with ASD have treated all
participants with ASD as a single group (although one study in
children did not).22 Thus, it is unclear whether putative
abnormalities in Glx are present across the spectrum, that
is, whether they are a potential common pathway, and/or
relate to particular core symptoms.
Hence, in this study, we used [1H]MRS to investigate
differences in brain glutamate and other metabolites in adults
with ASD. We compared controls with ASD people diagnosed
with the narrow ‘core’ disorder, who scored above cutoff on
research diagnostic criteria, and those with a broader
phenotype, who only met some of the criteria.
We focused on regions previously implicated in ASD
pathology and symptomatology: the basal ganglia and the
dorsolateral prefrontal cortex (DLPFC). For example, (1)
anatomical and metabolic abnormalities have been reported
in both of these interconnected areas in ASD;23,24 (2) the
basal ganglia have been linked with social and emotional
differences25 and compulsive and repetitive behaviours26 and
(3) the DLPFC has been linked to deficits in executive
function27 and theory of mind.28 Hence, we also correlated
[1H]MRS measures that differed significantly between groups
with scores on the Autism Diagnostic Interview—Revised
(ADI-R) interview.
We also included a ‘control’ region, in the medial parietal
lobe, which has not been linked to ASD and where no
differences were seen in a previous [1H]MRS study.18
Materials and methods
Participants. We recruited 42 adult participants: 28 indivi-
duals with ASD and 14 healthy controls matched for age,
gender and IQ (see Table 1). All participants had an IQ
above 65. We recruited only participants who reported being
right-handed, to avoid possible lateralization effects given
our use of unilateral [1H]MRS voxels.
The 28 participants in the ASD group were further divided
into two subtypes on the basis of their symptom profile. Fifteen
were diagnosed with the ‘narrowly defined phenotype’ of
autism based on the fact that they met the ADI-R cutoff criteria
in all three symptom domains and fulfilled the diagnostic
criteria for childhood autism or Asperger’s syndrome accord-
ing to the ICD-10 Research Classification of Mental and
Behavioural Disorders1 (criteria F84.0 and F84.5, respec-
tively). The other 13 individuals were classified as having the
‘broader phenotype’, that is, they did not meet the ADI-R cutoff
in one domain (see Table 1), but fulfilled the ICD-10 diagnostic
criteria for atypical autism (F84.1).
All individuals with ASD were recruited through London’s
Maudsley Hospital Behavioural Genetics Clinic, a specialist
diagnostic service.
Potential participants were excluded if they had a comorbid
psychiatric or medical disorder affecting brain development
(e.g. epilepsy or psychosis), a history of head injury, a genetic
disorder associated with ASD, for example, tuberous sclero-
sis or fragile X syndrome, or an IQ below 65. Participants with
ASD suffering from anxiety or depressive disorders were not
excluded, given the high frequency of these comorbidities in
ASD. According to participant self-report, all participants were
medication naive at the time of scanning.
All participants provided written informed consent. Ethical
approval for this study was provided by South London and
Maudsley/Institute of Psychiatry NHS Research Ethics
Committee, study reference 1997/087.
[1H]MRS data acquisition. [1H]MRS data were acquired on
a 1.5T GE HDx magnetic resonance imaging (MRI) scanner
(GE Medical Systems, Milwaukee, WI, USA) equipped with
TwinSpeed gradients.
The scanning protocol included a structural MRI scan,
namely a three-dimensional fast inversion-recovery-prepared
gradient echo acquisition (number of slices¼ 146, slice
thickness¼ 1.2mm, inversion time (TI)¼ 300ms, repetition
time (TR)¼ 11ms, echo time (TE)¼ 5ms, field of
Table 1 Participant demographic and clinical characteristics
Narrow ASD Broader ASD Control F P-value
Number 15 13 14 N/A
Number female 1 1 3
Age (years) 29 (6.0) 27 (6.4) 34 (8.8) 2.86 0.07
FSIQ 95 (13) 103 (16) 107 (21) 1.63 0.21
VIQ 95 (16) 101 (20) 106 (19.0) 1.21 0.31
PIQ 96 (19) 106 (12) 107 (21) 1.47 0.24
ADI-R
A domain
16.5 (4.2) 8.7 (2.4) N/A
ADI-R
B domain
10.7 (2.4) 6.3 (2.6)
ADI-R
C domain
3.9 (0.8) 1.8 (1.5)
Abbreviations: ADI-R, Autism Diagnostic Interview—Revised; Domain A, social
interaction; FSIQ, full-scale IQ; Domain B, communication; Domain C,
restricted and repetitive patterns of behaviour; HFA, high functioning autism;
N/A, not applicable; PIQ, performance IQ; VIQ, verbal IQ.
Values are expressed as mean (s.d.), unless otherwise indicated.
Note: The healthy control group did not receive an ADI-R assessment.
Therefore, there are no ADI-R scores for this group.
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view¼ 310mm, flip angle¼ 181, matrix¼ 256 160 over a
310 194mm field of view, giving 1.2 1.2 1.2mm3
voxels). This structural MRI was used for the localization of
the spectroscopy voxels in each participant.
Single voxel [1H]MRS spectra were then acquired, using a
point-resolved spectroscopy sequence. Point-resolved spec-
troscopy parameters were: TR¼ 3000ms and TE¼ 30ms.
A voxel of interest was positioned in the left basal ganglia
(20 20 15mm3). This voxel included parts of the head of
the caudate, the anterior putamen and the internal capsule.
Voxel of interests were also positioned in the left DLPFC
(16 24 20mm3) and in the left medial parietal lobe
(20 20 20mm3), using previously described methods.29
See Figure 1 for an illustration of the location of the voxels.
Data processing. [1H]MRS spectra were processed using
the LCModel software version 6-1-0 (Stephen Provencher
Incorporated, Oakville, Canada). LCModel uses a linear
combination of model spectra of metabolite solutions in vitro
to analyse the major resonances of in vivo spectra. In this
case, a basis set of alanine, aspartate, creatine (Cr),
g-aminobutyric acid (GABA), glutamine, glutamate, glycer-
ophosphocholine, mI, lactate, N-acetylaspartate (NAA),
N-acetyl-aspartylglutamate, scyllo-inositol and taurine,
together with a baseline function, were used for the analysis.
Each spectrum was reviewed to ensure adequate signal-to-
noise ratio, as well as the absence of artefacts. Note that the
NAA resonance at 2 p.p.m. contains both NAA and N-acetyl-
aspartylglutamate; we report here results reflecting the
combination of NAAþN-acetyl-aspartylglutamate, and use
the term NAA for brevity.
Calculation of absolute metabolite concentrations.
Metabolite concentrations for NAA, Cr, Glx and choline
(Cho) were calculated, in institutional units, as follows. The
raw metabolite estimates (LCModel output) were first
corrected by reference to calibration data from a phantom,
containing an aqueous solution of known NAA concentration.
One phantom [1H]MRS spectrum was acquired at the end of
each scanning session. The amplitude of the phantom NAA
peak was used to derive a correction factor, by which all
metabolite values for the scan were multiplied.
Furthermore, partial volume effects (group differences in
proportions of gray matter, white matter and cerebrospinal
fluid, CSF, in the [1H]MRS voxels) are a potential confound in
spectroscopy. This could be especially relevant to the present
investigation, given previously reported volumetric differ-
ences between ASD individuals and controls, for example,
in the basal ganglia.23,26
Therefore, to guard against such confounds, we deter-
mined the percentage of gray matter, white matter and
CSF within each [1H]MRS voxel for each participant. We
first segmented the T1-weighted structural MRI using
an automated procedure, spm_segment, part of the
Statistical Parametric Mapping software package (SPM2;
http://www.fil.ion.ucl.ac.uk/spm/software/spm2/; Wellcome
Trust Centre for Neuroimaging, London, UK).
The position of each individual [1H]MRS voxel relative to the
corresponding structural was determined, using positional
coordinates embedded in the raw spectra data files. The %
grey, white and CSF composition of each voxel was then
calculated automatically using in-house software. Finally, all
metabolite concentrations were corrected for the amount of
CSF in the voxel—under the assumption that CSF only
contains negligible quantities of the metabolites of interest—
by multiplying values by an individual correction factor¼
1/(1ProportionCSF), where ProportionCSF could range from
0 to 1, calculated separately for each voxel from each
participant. This was applied after correcting for phantom
NAA values (see above).
In summary: Metabolitecorrected¼Metaboliteraw (Phantom-
NAAknown/PhantomNAAobserved) (1/(1ProportionCSF)).
Statistical analysis. Age and IQ were compared using one-
way analysis of variance (ANOVA) across the three groups
(healthy control, broad ASD and narrow ASD).
Differences in mean metabolite concentrations were
calculated using a series of one-way ANOVAs, with group
as a between-subjects factor. One such ANOVA was
performed for each of the four metabolites, in each of the
three voxels, a total of 12 ANOVAs. As this procedure involves
multiple (12) comparisons, we applied a Bonferroni correction
to guard against Type I errors. We report results both before
and after this correction.
Planned post hoc independent sample t-tests were then
applied, in metabolites where a significant between-group
difference was found on the ANOVA, to evaluate differences
between (a) narrow ASD and healthy controls, (b) broader
ASD and healthy controls and (c) between the two ASD
groups (narrow vs broad).
Figure 1 Examples of the location of proton magnetic resonance spectroscopy ([1H]MRS) voxels. Three voxels were positioned in (a) left basal ganglia (20 20 15 mm3)
to include the head of the caudate, putamen and internal capsule, (b) left dorsolateral prefrontal cortex (16 24 20 mm3) and (c) left medial parietal lobe (20 20 20 mm3).
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We examined possible correlations between concentra-
tions of metabolites that differed significantly from controls in
these t-tests against ADI-R domain scores, across the whole
combined ASD group, using Pearson’s product–moment
correlation coefficients.
All analyses were performed using SPSS 15.0 software
(SPSS, Chicago, IL, USA).
Results
Demographics. Groups did (Table 1) not differ significantly
in age, full-scale IQ, verbal IQ or performance IQ.
Tissue composition and data quality. Groups did not
differ significantly in mean voxel % grey matter, white matter
or CSF in any of the three voxels (Table 2). This is
unsurprising as, although volumetric differences have been
observed in ASD in the basal ganglia26 and cortex,30 these
were of small magnitude, and would not be expected to
materially affect composition of hand-placed voxels.
To verify that the quality of the [1H]MRS data did not vary
between groups, we compared the LCModel 6-1-0 Cramer-
Rao Lower Bound estimate standard deviations for each
metabolite in each voxel, using a one-way ANOVA across the
three groups. This revealed no significant differences (all
F(2,42)o2.8, all P40.07.) See Figure 2 for an example of a
[1H]MRS spectrum after model fitting.
Finally, because of the potential risk of ‘drift’ in extended
[1H]MRS investigations (in which metabolite estimates on the
same scanner change over long periods of time), we
compared the timings of scans across the three groups, in
terms of days after the first scan of the series. This revealed no
significant difference (one-way ANOVA F(2,44)¼ 0.739,
P¼ 0.484). Scan date was also not correlated with the
value of any metabolite in any voxel (all Pearson’s ro0.23,
all P40.13).
Metabolite differences
Basal ganglia. There was a significant group effect in every
metabolite concentration we measured in this voxel
(ANOVA) (Table 3). Two of these effects—Cr and Glx—
survived conservative Bonferroni correction for multiple
comparisons over all metabolites and voxels. Post hoc
independent sample t-tests showed that Glx concentrations
were significantly lower in both the ‘restricted’ and ‘broader’
ASD phenotypes compared with controls (see Figure 3).
Both Cr and NAA showed a similar pattern. Cho was also
lower in both ASD groups as compared with controls, but this
only reached statistical significance in the broader ASD
phenotype.
There were no significant differences between the two ASD
subgroups in any metabolite concentration.
To establish whether the finding of lower Glx remained
significant after controlling for tissue composition and the
other metabolite concentrations, we performed a univariate
GLM covarying for basal ganglia grey/white matter, Cr, NAA,
Cho, age and IQ. The findings remained significant
(F¼ 3.530, Po0.05).
Dorsolateral prefrontal cortex. There was no significant
effect of group for Glx or Cho. However, there were
significant effects of Cr and NAA, although neither of these
differences survived conservative Bonferroni correction. Post
hoc tests revealed that Cr was significantly lower in both ASD
groups relative to healthy controls, whereas NAA was
significantly lower only in the ‘narrow’ ASD phenotype.
However, there were no significant differences between the
two ASD subgroups.
Table 2 Voxel tissue composition of grey matter, white matter and CSF
ANOVA
Region Measure Narrow ASD s.d. s.d. Control s.d. F P-value
Basal ganglia Grey matter 62.20% 12.94% 64.99% 6.01% 54.31% 16.49% 2.65 0.084
White matter 35.68% 13.07% 33.04% 5.12% 43.84% 17.13% 2.73 0.078
CSF 2.09% 1.45% 1.92% 1.57% 1.82% 1.66% 0.16 0.849
DLPFC Grey matter 45.35% 14.48% 45.32% 14.01% 2.17% 14.37% 0.38 0.685
White matter 48.79% 17.57% 49.37% 16.70% 54.06% 17.34% 0.68 0.685
CSF 5.67% 4.03% 5.07% 3.39% 4.03% 3.58% 0.76 0.476
Parietal lobe Grey matter 44.47% 7.94% 47.61% 7.62% 44.89% 6.33% 1.03 0.366
White matter 35.16% 14.10% 34.47% 11.98% 38.39% 11.43% 0.35 0.706
CSF 19.34% 14.28% 15.75% 6.86% 16.09% 7.56% 0.48 0.625
Abbreviations: ANOVA, analysis of variance; ASD, autism spectrum disorder; CSF, cerebrospinal fluid; DLPFC, dorsolateral prefrontal cortex.
Figure 2 Example of a proton magnetic resonance spectroscopy ([1H]MRS)
spectrum showing LCModel 6-1-0 fit.
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Parietal region. As predicted, no significant differences were
found in any metabolite concentration between any of the
groups, even before Bonferroni correction.
Relationship to behavioural variables. Across the com-
bined ASD group (both broader and narrow phenotype),
lower basal ganglia concentration of Glx was significantly
correlated with worse scores on the ADI-R Communication
Scale (i.e. more abnormal Glx concentrations were asso-
ciated with greater communication impairment (r¼  0.465,
P¼ 0.013, n¼ 28; see Figure 4). This correlation was specific
to this metabolite and this symptom domain: no correlations
were seen in other metabolites or domains.
We further examined this association within each group
separately. There was no significant correlation in the
narrowly defined autism group (r¼  0.224, P¼ 0.422), but
there was in those with the broader phenotype (r¼  0.805,
P¼ 0.001).
Discussion
We found that adults with ASD have a significantly reduced
Glx concentration in the basal ganglia as compared with
controls. Our preliminary evidence further suggests that that
this reduction was (1) regionally specific, that is, there were no
Table 3 Metabolite concentrations in BG, DLPFC and parietal cortex [1H]MRS voxels and group differences
ANOVA Post hoc t-tests—P-valuesb
Region Metabolitea Narrow ASD Broader ASD Control F P-values Narrow
ASD vs controls
Broad ASD vs
controls
Broad ASD vs
narrow ASD
Basal ganglia Glx 10.12 (1.14) 10.43 (1.26) 12.34 (1.45) 12.63 o0.0001c o0.001 0.001 0.25
Cho 1.205 (0.19) 1.098 (0.14) 1.324 (0.19) 5.83 0.006d 0.212 0.004 0.44
Cr 5.097 (0.65) 5.323 (0.53) 6.435 (1.25) 10.02 0.0003c o0.001 0.004 0.47
NAA 5.454 (0.81) 5.486 (0.42) 6.458 (1.52) 4.54 0.017d 0.030 0.045 0.32
DLPFC Glx 7.492 (1.11) 7.156 (1.51) 8.007 (1.42) 1.36 0.27 — — 0.32
Cho 1.129 (0.21) 1.110 (0.16) 1.271 (0.27) 2.35 0.11 — — 0.93
Cr 4.074 (0.48) 4.021 (0.49) 4.602 (0.60) 5.32 0.009d 0.027 0.017 0.64
NAA 5.954 (0.79) 5.955 (0.47) 6.660 (0.95) 4.07 0.025d 0.047 0.057 0.22
Parietal Glx 10.607 (2.79) 9.790 (1.65) 11.028 (1.62) 1.31 0.28 — — 0.41
Cho 1.112 (0.37) 1.048 (0.13) 1.149 (0.25) 0.53 0.59 — — 0.524
Cr 5.461 (1.42) 5.140 (0.81) 5.382 (0.70) 0.39 0.68 — — 0.19
NAA 7.998 (2.32) 7.472 (0.76) 7.887 (1.06) 0.48 0.62 — — 0.31
Abbreviations: ANOVA, analysis of variance; ASD, autism spectrum disorder; BG, basal ganglia; Cho, choline; Cr, creatine; DLPFC, dorsolateral prefrontal cortex;
Glx, glutamate and glutamine; [1H]MRS, proton magnetic resonance spectroscopy; NAA, N-acetylaspartate.
aData are expressed asmean (s.d.). bPost hoc t-tests comparing ASD cases with controls were only performed when ANOVAwas significant at uncorrected Po0.05.
cBold figures show values significant at P¼ 0.05 level, with Bonferroni correction over 12 comparisons, that is, uncorrected Po0.0047. dSignificant at P¼0.05 level
before Bonferroni correction.
Figure 3 Individual participant data showing basal ganglia glutamate and
glutamine (Glx) by group. ASD, autism spectrum disorder.
Figure 4 Association between basal ganglia glutamate and glutamine (Glx) and
Autism Diagnostic Interview—Revised (ADI-R) Communication Subscale Score in
individuals with autism spectrum disorder (ASD).
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significant differences in the other cortical regions we
examined; (2) a potential final common pathway in ASD, as
it was present in both ‘narrow’ and ‘broadly’ defined ASD; and
(3) was associated with some aspects of clinical variation
(social communication).
We suggest that it is unlikely that our findings can be fully
explained by potential confounds, such as differences in voxel
tissue composition, age, IQ or medication. There were no
significant between-group differences in voxel grey matter,
whitematter andCSF, and all metabolite valueswere corrected
for CSF%. Demographic variables such as age, gender and IQ
were not different between the groups, all participants were
right handed and all of the individuals we studied were
psychotropic medication naive according to self-report.
This is the first [1H]MRS study to report on Glx in the basal
ganglia of adults with ASD. Our finding of reduced Glx in the
basal ganglia (predominantly the lentiform nuclei) agrees with
studies finding reductions of Glx in the cingulate cortex and
the thalamus,19 but contrasts with our previous finding of
increased Glx in the amygdala-hippocampal cortex in adults
with ASD.18 Also, similar to prior studies, we found no
differences in the parietal cortex.18
Taken together, these results demonstrate that, rather than
being a ‘global’ neurobiological abnormality, Glx changes
seen in ASD are highly regionally specific, suggesting that the
underlying neurobiological cause(s) are also localized.
Reductions in Glx could result simply from a local reduced
density of glutamatergic synapses and neurons, such as
reduced storage capacity and turnover, but could also be the
product of alterations in glutamate and glutamine metabolism.
In neurons, glutamate is synthesized from glutamine via
glutaminase, but after release in the synapse, glutamate is
converted back into glutamine in glial cells, by glutamine
synthetase. Glutamate is also converted to GABA by the
neuronal enzyme glutamate decarboxylase (GAD).5
Alterations in GAD expression could be a potential
explanation for the fact that we observed reduced Glx in the
basal ganglia. This hypothesis would also help to reconcile
these results with the suggestion that individuals with ASD
have an inhibitory signalling deficit and an increased ratio of
excitatory glutamate to inhibitory GABA transmission.8,31 It is
possible that, while the Glx signal was reduced, the ratio
between glutamate and GABA was still increased. Reduced
glutamate would be expected to lead to a corresponding
reduction in GABA synthesis, as glutamate is the precursor of
GABA. If GAD activity were reduced, one would expect a
lower GABA:Glx ratio.
Unfortunately, there have not yet been any studies
examining GAD expression in the basal ganglia in ASD, but
studies of other brain regions have shown regionally specific
differences associated with the disorder. For example, GAD
has been reported to be decreased in cerebellar Purkinje
cells,32 but increased in cerebellar interneurons,33 in ASD.
A further possibility is that the observed differences in Glx
are secondary to alterations in other neurotransmitter
systems. For example, the basal ganglia are densely
innervated by serotonergic projections, which exert complex
modulatory effects on glutamate and GABA release.34 We
and others reported reduced density of cortical 5HT2A
(serotonin 2A) receptors and serotonin transporter in the
cortex and midbrain,35–37 (although see Girgis et al.38) the
same pattern has been found in the parents of children with
ASD.39 Further, some have reported that children with ASD
have significant differences in serotonin synthesis.40 Hence, it
could be that serotonergic abnormalities underlie the differ-
ences in Glx we observed—either indirectly via influences on
neurodevelopment or through direct action on glutamate
metabolism.
Also, in the context of previous findings, our results suggest
that within ASD age may be an important moderator of both
cortical and subcortical differences in brain Glx. Specifically,
prior [1H]MRS studies in children with ASD reported wide-
spread decreases in cortical Glx14—but no differences in the
basal ganglia.16,17 This is the opposite of the pattern we
observed in adults, namely no differences in the cortical
regions (DLPFC and parietal lobe), but a reduction in the basal
ganglia. This is consistent with the idea of autism as a disorder
of brain maturation.41 We were unable to address age effects
directly, as this study did not include children—but this is a
focus of our ongoing studies.
The correlation between basal ganglia (Glx) and the
severity of social communication impairments in ASD is
consistent with the known involvement of this area in various
aspects of language and communication. For example,
functional imaging studies demonstrated that the caudate
and putamen are involved in ‘higher level’ aspects of
language, such as inferring with the implied as opposed to
literal meaning of sentences,42 and resolving ambiguous
sentences—functions that are characteristically impaired in
ASD.This correlationwas specific to the basal ganglia, however,
with no significant correlation seen in the DLPFC, an area also
known to be involved in communication and Theory of Mind.28
One explanation for this could be that alterations in neuro-
transmitters other than glutamate are responsible for DLPFC
dysfunction in autism; serotonin is one possibility, as a pre-
vious study found that lower cortical 5HT2A receptor binding
is associated with communication impairments in ASD.37
We are only able to report a correlation between ASD in
adults (and in particular, Social Communication symptoms as
measured by the ADI-R) and reduced basal ganglia Glx
levels. Hence, we cannot be certain whether the differences in
Glx are the cause of the ASD symptoms. It is possible that
they represent a downstream effect of the symptoms if, for
example, the lack of social interaction or high-level language
use engaged in by people with ASD led, over time, to
neuroplastic changes in corticobasal circuits. However, we do
not believe that this can explain all our results, because the
ADI is a measure childhood (developmental) symptoms in the
first years of life.
In addition to the findings related to glutamate, discussed
above, we also observed reduced levels of Cho, Cr and NAA
in the basal ganglia, and of Cr and NAA in the DLPFC, in
individuals with ASD, although only the basal ganglia Cr
difference survived conservative Bonferroni correction. The
finding of reduced Cr and NAA in both the basal ganglia and in
the DLPFC is consistent with previous [1H]MRS studies in this
area in ASD.14,15,22 However, we have previously29 reported
increased NAA, Cr and Cho in the medial prefrontal cortex of
adults with Asperger’s syndrome, underlining that the
differences seen are regionally specific. Also in line with prior
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work,18,29 we did not observe any significant metabolite
differences in the parietal cortex control region. This confirms
that the effects observed in the basal ganglia and the DLPFC
are regionally specific.
As both Cr and NAA are involved in neuronal energy
metabolism, our finding of local reductions in these metabo-
lites in the basal ganglia and the DLPFC may indicate either
metabolic dysfunction in these areas or a reduced density of
metabolically active neurons. If the latter, this may also
explain the observed reduction in Cho in the basal ganglia (as
this is a component of cell membranes).
Another important implication of our finding of reduced Cr in
ASD in the basal ganglia andDLPFC is that it may be invalid to
express the concentration of metabolites such as NAA and
Glx as ratios to Cr in the same voxel. This approach is
commonly used in [1H]MRS studies,22,43 as it is widely
assumed that Cr is constant; our findings suggest the this is
not true in adults with ASD.
However, our study does have a number of limitations. We
obtained [1H]MRS data on a 1.5T MRI scanner. At 1.5 T, it is
not possible to distinguish between the compounds that
contribute to the ‘Glx’ signal, that is, glutamate and glutamine.
Future studies at 3 T or higher are needed to distinguish these
compounds, but previous studies have cautiously attributed
reductions in Glx to glutamate, as glutamate constitutes the
most abundant central neurotransmitter.14,15,18
Another limitation is that we only recruited people with a
normal or above-normal IQ, and excluded those with a history
of epilepsy or seizures. This served to increase the homo-
geneity of the sample and ensure that any differences
observed were associated with symptoms of ASD per se,
but it means that the results may not be representative of the
entire ASD population, as many people with ASD also suffer
from a below-normal IQ and/or epilepsy.1 Future studies
should examine this population.
In summary, we found preliminary evidence that adults with
ASD (both narrowly and broadly defined) have significant
differences in brain glutamate and/or glutamine metabolism.
This may be a final ‘common pathway’ in the disorder, and
underpin some clinical symptoms. Further work is required to
determine the cause(s) of this putative abnormality.
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